Fulcrum Therapeutics, Inc. (NASDAQ:FULC – Get Rating) has been given a consensus rating of “Hold” by the nine ratings firms that are covering the firm, reports Marketbeat.com. One equity research analyst has rated the stock with a sell recommendation, four have assigned a hold recommendation and two have issued a buy recommendation on the company. The average 1-year price objective among brokerages that have updated their coverage on the stock in the last year is $10.00.
Several analysts have recently issued reports on the stock. Bank of America cut shares of Fulcrum Therapeutics from a “neutral” rating to an “underperform” rating in a research report on Friday, February 24th. Credit Suisse Group cut shares of Fulcrum Therapeutics from an “outperform” rating to a “neutral” rating and reduced their price target for the stock from $11.00 to $8.00 in a research report on Friday, March 10th. SVB Securities cut their target price on shares of Fulcrum Therapeutics from $18.00 to $10.00 in a research note on Friday, March 10th. Stifel Nicolaus lowered shares of Fulcrum Therapeutics from a “buy” rating to a “hold” rating and cut their target price for the stock from $35.00 to $6.00 in a research note on Thursday, March 9th. Finally, Oppenheimer cut their target price on shares of Fulcrum Therapeutics from $26.00 to $20.00 and set an “outperform” rating on the stock in a research note on Monday, February 27th.
Hedge Funds Weigh In On Fulcrum Therapeutics
A number of hedge funds have recently modified their holdings of the business. ProShare Advisors LLC acquired a new stake in shares of Fulcrum Therapeutics during the first quarter worth $29,000. JPMorgan Chase & Co. lifted its holdings in shares of Fulcrum Therapeutics by 3.0% during the first quarter. JPMorgan Chase & Co. now owns 190,269 shares of the company’s stock worth $543,000 after purchasing an additional 5,583 shares during the period. State Street Corp lifted its holdings in shares of Fulcrum Therapeutics by 23.7% during the first quarter. State Street Corp now owns 965,588 shares of the company’s stock worth $2,752,000 after purchasing an additional 185,174 shares during the period. Squarepoint Ops LLC acquired a new stake in shares of Fulcrum Therapeutics during the first quarter worth $911,000. Finally, Geode Capital Management LLC lifted its holdings in shares of Fulcrum Therapeutics by 24.2% during the first quarter. Geode Capital Management LLC now owns 1,062,634 shares of the company’s stock worth $3,029,000 after purchasing an additional 206,802 shares during the period.
Fulcrum Therapeutics Price Performance
NASDAQ FULC opened at $2.91 on Friday. The firm’s 50-day moving average is $2.91 and its two-hundred day moving average is $6.64. Fulcrum Therapeutics has a 12 month low of $2.25 and a 12 month high of $15.00. The stock has a market capitalization of $179.72 million, a P/E ratio of -1.29 and a beta of 2.12.
Fulcrum Therapeutics (NASDAQ:FULC – Get Rating) last issued its quarterly earnings results on Thursday, March 9th. The company reported ($0.50) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.49) by ($0.01). The business had revenue of $0.69 million for the quarter, compared to analyst estimates of $1.92 million. Fulcrum Therapeutics had a negative return on equity of 49.35% and a negative net margin of 2,687.81%. As a group, analysts anticipate that Fulcrum Therapeutics will post -1.82 EPS for the current year.
About Fulcrum Therapeutics
(Get Rating)
Fulcrum Therapeutics, Inc. is a clinical stage biopharmaceutical company. The firm develops new medicines and focuses on unlocking gene control mechanisms to develop small molecule therapies. Its product candidate includes Losmapimod and FTX-HbF. The company was founded by Michael R. Green, Danny Reinberg, Rudolf Jaenisch, Jeannie T.
Read More
Receive News & Ratings for Fulcrum Therapeutics Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Fulcrum Therapeutics and related companies with MarketBeat.com’s FREE daily email newsletter.